Manage episode 334976847 series 3349924
In today's episode, Stan introduces the three major platforms for drug discovery. These are the technology platforms on which most of the drugs on the market and in development today are produced. By understanding the difference between these platforms, the listener can understand the differences between the drugs produced on these platforms.
The three main platforms for drug discovery are small molecule drugs, monoclonal antibodies, and RNA targeting drugs. Small molecule drugs are well small – what that means in science is they are considered to be less than 500 daltons in size. Small molecule drugs are the basis for the drug discovery industry and account for most of the earlier drugs that reached the commercial market. In later years, monoclonal antibodies and RNA-targeted therapies began to gain in popularity due to their higher degree of specificity and the broad applicability of these technologies. At n-Lorem, we take advantage of the high specificity, efficiency and speed of RNA-targeted technology to discover drugs for our nano-rare patients. In this episode, the listener will learn the differences between the three platforms, the benefits of each platform and why gene therapy is not on the list, yet. By understanding the different drug modalities (small molecule, monoclonal antibodies or RNA-targeted therapy) the listener will understand the benefits and limitations of these very different approaches to drug discovery.
As many equate drugs with cures, taking a drug for a particular disease or condition does not always mean that the disease or condition is cured. Additionally, it is important to understand that drugs can produce harm as well as benefit. This risk/benefit profile is always a consideration in the development of any drug from any platform.